Business - Briefly   

Ranbaxy Pharma in pact with Zenotech

GURGAON: Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced on Wednesday that RPI has entered into an agreement with Zenotech Laboratories of Hyderabad. Under the agreement, Zenotech Labs will develop, submit for regulatory approval and manufacture 11 oncology products which Ranbaxy will market as generic formulations in the U.S. and Canada under the Ranbaxy label. The combined branded sales of these products are estimated at $3.7 billion, according to a release.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Maran supports Nasscom plea to extend STPI scheme
Global uncertainty dogs Indian bourses
Motorola to focus on sub-$30 handsets
CSE members opt for demutualisation
BOC to supply gases to JSW Steel
New CMD for South Eastern Coalfields
SBT MD calls on CM
Major initiatives to strengthen rubber sector: Minister
Malaysian Govt. to open new visa office in Mumbai
CITU seeks ILO intervention on price index issue
U.S. consortia await semiconductor policy
Indian Bank launches ACU operations
L& T recommends 1:1 bonus
Indiabulls selects Nucleus solution
Rupee drops further against dollar
Exchange rates
Bullion rates
Gas find in KG basin
TRAI directive on credit limit
GMR Infrastructure IPO by June-end
Anti-dumping duty on saccharin from China
Ranbaxy Pharma in pact with Zenotech
Lanco group bags Anpara 1,000 MW power project
Indiabulls selects Nucleus solution
GM Solutions acquires shares of R Systems
Aztec Sofwate unveils new brand identity
Capgemini to double headcount in India
Vijaya Bank revises FCNR (B) deposit rates
Canarys Automations introduces new product
Infosys partners NorthStar

Copyright © 2006, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu